Compare iShares MSCI South Korea ETF (EWY) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Hims and Hers Health Inc — how do they compare? iShares MSCI South Korea ETF trades at $178.33 (market cap $26.25B), while Hims and Hers Health Inc trades at $28.43 (market cap $6.55B). The key difference: iShares MSCI South Korea ETF is far larger — about 4× Hims and Hers Health Inc's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Hims and Hers Health Inc for 21 Days on average.
| EWY | HIMS | |
|---|---|---|
Market Cap | $26.25B | $6.55B |
Volume | 19,056,075 | 14,842,814 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $62.76 |
52-Week Low | $80.72 | $14.52 |
Typical Hold Time | 46 Days | 21 Days |
Enterprise Value | — | $7.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $183.72, down 1.44% amid mixed technical signals and KOSPI volatility driven by semiconductor sector sensitivity. The ETF shows neutral momentum with bullish moving averages but faces resistance near $185. Recent news highlights South Korea's strong 2026 market performance and AI-driven semiconductor demand, though concerns persist about high oil prices and rising US yields impacting tech valuations.
Outlook remains cautiously optimistic given EWY's heavy concentration in Samsung and SK hynix, which benefit from AI memory cycle strength. Key risks include reliance on two stocks, geopolitical tensions, and macroeconomic pressures. The ETF offers exposure to South Korea's tech-led growth but requires monitoring of memory cycle trends and foreign investor flows.
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
